Pediatric psychopharmacology operates with two important framing facts: FDA-approved indications in children are limited, but off-label evidence-based use is common and often appropriate; and the developmental, family, and educational contexts of pediatric care shape decisions in ways adult prescribing rarely does.
- Class
- Pediatric prescribing framework
- Mechanism
- Developmental considerations: developing brain, pharmacokinetic differences (rapid metabolism in young children — sometimes need higher mg/kg doses), behavioral context, family system
- FDA indications
- ADHD (well-established), depression/anxiety (selected agents in adolescents), bipolar (limited), psychotic disorders, autism-associated irritability
- Key adverse effects
- Variable by agent. Class concerns: growth effects (stimulants), suicidality (antidepressants — black box), metabolic effects (antipsychotics often more pronounced in pediatric)
Black box: SSRIs/antidepressants: suicidality in pediatric and young adult patients
FDA-approved pediatric indications limited — but off-label use is common and often supported by evidence. Approved: fluoxetine (MDD ≥8, OCD ≥7), escitalopram (MDD ≥12, GAD ≥7), sertraline (OCD ≥6), several SSRIs for OCD; stimulants/atomoxetine for ADHD; aripiprazole/risperidone for irritability in autism; aripiprazole/olanzapine/quetiapine/risperidone for adolescent schizophrenia and bipolar mania. Lithium ≥7 for bipolar mania.
Developmental pharmacology matters. Children often metabolize drugs faster than adults — higher milligram-per-kilogram dosing is sometimes needed. The developing CNS may respond differently to psychiatric medications, and long-term implications of medication exposure during development are not always known with adult-level certainty. Behavioral context shapes both diagnosis and treatment — the child whose ADHD is mostly visible at school requires school engagement; the adolescent with depression may need family involvement.
Pediatric psychopharmacology accounts for a developing brain and body — altered pharmacokinetics, distinct safety signals, and a narrower evidence base.
Mechanism note: Pediatric prescribing reflects a developing system — altered kinetics, the antidepressant suicidality warning, stimulant growth monitoring — within a narrower, often off-label evidence base.
FDA-approved pediatric indications include: fluoxetine for MDD (≥8 years) and OCD (≥7); escitalopram for MDD (≥12) and GAD (≥7); sertraline for OCD (≥6); several stimulants and atomoxetine for ADHD; aripiprazole and risperidone for irritability in autism; aripiprazole/olanzapine/quetiapine/risperidone for adolescent schizophrenia and bipolar mania; lithium ≥7 for bipolar mania. Plenty exists; not everything pediatric is off-label.
Black-box suicidality warnings for antidepressants in pediatric and young adult patients (up to age 24) reflect a real but small clinical trial signal. Counsel, monitor, and continue when treatment is indicated — but don't let the warning prevent appropriate treatment of severe depression. Untreated severe pediatric depression carries substantial risks including completed suicide.
Family involvement is part of the work. Get to know the family system. Discuss adherence, monitor side effects from a family perspective, engage parents in psychoeducation. School is often the third party that needs information — coordinate with educational team where relevant.
Mandated reporting obligations apply more frequently in pediatric practice. Suspected abuse, neglect, or specific danger require reporting. Maintain the clinical relationship through and after the reporting process when possible.
Pediatric prescribing is rewarding work that requires developmental sensitivity, family partnership, and willingness to engage with the broader system around the child.